20 June 2013
Keywords: fda, approval, gsk, requip, pd, treatment, uk-based
Article | 23 June 2008
UK-based drug major GlaxoSmithKline's Requip XL (ropinirole extended-release tablets), an oral once-daily non-ergot dopamine
agonist, has been approved by the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 June 2008
16 June 2008
19 June 2013
© 2013 thepharmaletter.com